RxDoctor Payments Data

Boyd Helm, MD

Interventional Cardiology · Baton Rouge, LANPI 1073514576

Payments from drug & device makers

$3,436in general payments, 2019–2025

Across 203 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$812
  • Irhythm Technologies, Inc.$473
  • Boston Scientific$377
  • Pfizer$267
  • Novartis$213
  • Alnylam Pharmaceuticals Inc.$181
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,436 in reported general payments places this provider in the 20th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$712,159
Medicare patients
487
Services billed
13,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,005$948,055
EntrestoSacubitril/Valsartan258$231,619
Repatha SureclickEvolocumab178$133,730
XareltoRivaroxaban114$104,199
Ezetimibe1,903$37,239
VascepaIcosapent Ethyl55$30,427
Repatha SyringeEvolocumab32$26,751
MounjaroTirzepatide16$16,796
Pravastatin Sodium727$15,614
Atorvastatin Calcium1,121$14,521
Rosuvastatin Calcium941$14,008
NexlizetBempedoic Acid/Ezetimibe15$9,996
FarxigaDapagliflozin Propanediol14$9,036
ClopidogrelClopidogrel Bisulfate869$9,017
Praluent PenAlirocumab16$7,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$267$948,0551,005 claims
NovartisEntresto$213$231,619258 claims
Johnson & JohnsonXarelto$106$104,199114 claims
Esperion Therapeutics, Inc.Nexlizet$161$9,99615 claims
AstraZenecaFarxiga$114$9,03614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →